其他隱形眼鏡護理產品

References: 1. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. The Ocular Surface. 2017;15(3):276-283. 2. Laurent T. Structure hyaluronic acid. EA Balazs (Ed.) Chemistry and molecular biology of intercellular matrix. Academic Press, London; 1970:703-732. 3. Aragona P, Papa V, Micali A et al. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol 2002;86:181-184. 4. Wolffsohn JS, Arita R, Chalmers R et al. TFOS DEWS II Diagnostic Methodology Report. Ocul Surf 2017;15:539-574. 5. Benelli U, Nardi M, Posarelli C et al. Tear osmolarity measurement using the TearLab osmolarity system in the assessment of dry eye treatment effectiveness. Cont Lens Anterior Eye 2010;33:61-67. 6. Montani G. Intrasubject tear osmolarity changes with two different types of eye drops. Optom Vis Sci 2013;90:372-377. 7. Huth S, Tran D, Skotnitsky C et al. Wavelength-dependent optical interferometry measurements of change in thickness of apical corneal tear film following eye drop instillation. ARVO abstract 2008:49:108. 8. Michaud L, Frenette B. Evaluation of sodium hyaluronate lubricating drops used before insertion of contact lenses on symptomatology, severity, and intensity of ocular dryness. ISRN Ophthalmol 2012:762784. 9. Hargittai I, Hargittai M. Molecular structure of hyaluronan: an introduction. Struct Chem 2008;19:697–717 10. Wasmanski A et al. Cross-Over Evaluation PEG-400 0.4% & 0.25% artificial tears in mild dry eye patients. Poster ARVO,2010. 11. Prabhasawat P et al. Performance profile of sodium hyaluronate in patients with lipid tear deficiency: randomised, double-blind, controlled, exploratory study. Br. J. Ophthalmol. 2007;91;47-50 12. Bitton et al. Comparison of Ocular Lubricant Osmolalities. Optom Vis Sci. 2017;94:694-699 IMPORTANT SAFETY INFORMATION: BLINK® Intensive Tears & BLINK® Contacts are for the temporary relief of burning, irritation and discomfort due to dryness of the eye or exposure to wind or sun, and may be used as a protectant against further irritation. Patients should stop use and contact their eye care practitioner if they experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours. BLINK® Intensive Tears & BLINK® Contacts are the trademarks of Bausch & Lomb Incorporated or its affiliates. All other product/brand names and/or logos are trademarks of their respective owners. © 2023 Bausch + Lomb, Inc. 2023 ®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates. HK-VC-2023-09-111